Skip to main content
Premium Trial:

Request an Annual Quote

Downloads and Upgrades: PathwayStudio, EMBL-Bank 115


Elsevier has launched a web-based version of Pathway Studio that incorporates biological data from Elsevier's biology journals in addition to journals obtained through collaborations with third-party publishers.

Pathway Studio is an integrated data mining and visualization software that lets users connect relevant biological facts and relationships, visualize these facts in context, as well as integrate and interpret experimental data. It is used for defining and testing in silico-based hypotheses across a wide range of disciplines including mechanistic modeling of disease, drug action and toxicity, target discovery and validation, biomarker discovery, cellular and network pathway building, protein-protein interactions, and more.

Elsevier acquired Pathway Studio when it bought the business assets of Ariadne Genomics in 2011 (BI 12/09/2011).

Release 115 of the European Nucleotide Archive/EMBL-Bank database is available from the European Bioinformatics Institute's ftp servers and other verified mirror sites.

Full release notes are available here.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.